Finerenone model places kidney and cardiovascular protection within reach at an NHS-acceptable price
In adults with chronic kidney disease and type 2 diabetes, the economic case for finerenone now sits alongside the clinical case. A lifetime Markov model evaluating finerenone added to background treatment versus background treatment alone in England and Wales found that the drug’s reduction in kidney and cardiovascular events translated into more quality-adjusted survival at a cost that remained within accepted cost-effectiveness boundaries for the National Health Service.
The analysis is clinically important because CKD in type 2 diabetes is not a single-organ problem. Progressive nephron loss and accelerated atherosclerotic risk move in parallel, and each event can trigger the next: albuminuria signals glomerular injury, declining filtration narrows therapeutic options, and cardiovascular complications often determine whether patients remain stable enough to benefit from long-term renal preservation. Finerenone’s value in the model came from interrupting both trajectories at once.
The cohort represented adults with stage 3 or 4 CKD and albuminuria associated with T2D, aligned with the relevant marketing authorization. Patient-level data from FIDELIO-DKD informed the model structure, which tracked kidney disease progression and cardiovascular risk through health states defined by kidney stage and cardiovascular event profiles. This approach matters because the economic burden of diabetic kidney disease is not driven only by dialysis or transplant endpoints; it also accrues through recurrent hospitalizations, cardiovascular deaths, and the downstream costs of surviving a major event with reduced renal reserve.
Event reduction translated into longer survival and better quality-adjusted life years
Finerenone plus background treatment produced measurable clinical gains in the modeled population. Patients experienced reduced rates of nonfatal cardiovascular events and cardiovascular deaths, and those event reductions drove improvements in both survival and quality-adjusted survival. Life years were 6.11 per patient with finerenone plus background treatment versus 5.97 with background treatment alone.
The QALY results followed the same pattern. Total discounted quality-adjusted life years reached 5.97 per patient with finerenone plus background treatment, compared with 5.84 for background treatment alone. In practical terms, the incremental benefit came from preserving health states in which patients avoided the immediate and lingering consequences of cardiovascular events while also slowing kidney deterioration. For a population with advanced CKD and diabetes, even modest shifts in event timing can have disproportionate effects on both length and quality of life, because each complication narrows the remaining clinical runway.
The biological plausibility is strong. Finerenone targets mineralocorticoid receptor signaling, a pathway implicated in inflammation and fibrosis within the kidney and vasculature. By dampening those processes, the drug can plausibly delay structural progression in renal tissue while also lowering the cardiovascular vulnerability that accompanies diabetic CKD. The modeled event reduction reflected that dual mechanism, rather than a narrow effect limited to laboratory markers.
Incremental cost remained modest against the health gains
Discounted per-patient costs were £48,940 with finerenone plus background treatment and £47,716 with background treatment alone. The incremental cost-effectiveness ratio came to £8,808 per QALY gained for finerenone plus background treatment versus background treatment alone.
That ICER is the central economic result. It places the added drug cost into context against the avoided burden of cardiovascular and renal events, which are among the most expensive complications in diabetic kidney disease care. Finerenone did not remove cost from the system; it shifted spending toward a therapy that generated additional health benefit and likely reduced the frequency of expensive downstream events. In a chronic disease model with lifetime horizon, that balance is often more important than the sticker price of the drug alone.
The findings also help explain why the model favored finerenone despite higher upfront treatment cost. Patients lived longer and spent more time in better health states, which raised total discounted costs only modestly relative to the gain in QALYs. The result was an incremental ratio well below thresholds commonly used in health technology assessment.
SGLT2 inhibitor uptake did not erode the economic case
A separate scenario analysis explored the impact of real-world data suggesting more frequent SGLT2 inhibitor use in the United Kingdom since FIDELIO-DKD. This is a critical test, because contemporary CKD care increasingly includes layered cardiorenal therapy, and any new economic estimate must remain credible in that setting.
The robustness of the ICER across sensitivity and scenario analyses strengthens the argument that finerenone retains value even when background therapy evolves. If more patients are already receiving SGLT2 inhibition, the incremental space for another protective agent may appear smaller at first glance. In practice, the modeled results suggest otherwise: finerenone still delivered a cost-effectiveness ratio that remained within the range typically considered acceptable, indicating that its benefit persists even in a more intensively treated population.
This matters at the bedside because CKD management in diabetes is increasingly cumulative rather than binary. Patients are not choosing between one perfect therapy and another; they are accumulating layers of risk reduction. A therapy that remains economically efficient in the presence of stronger background care is more likely to fit real-world prescribing patterns, where clinicians must weigh polypharmacy, renal stage, albuminuria burden, and long-term risk simultaneously.
What the model can and cannot answer
The analysis offers a persuasive health-economic argument, but it remains a model rather than a head-to-head clinical trial of resource use. Its conclusions depend on the durability of treatment effects observed in FIDELIO-DKD, the assumptions embedded in lifetime projection, and the way costs were assigned to future kidney and cardiovascular events. Those are standard features of cost-effectiveness work, yet they still require caution when translating the findings into reimbursement or formulary decisions.
Even so, the direction of effect is clinically coherent. CKD with T2D drives cost through repeated cardiovascular instability, progressive renal decline, and eventual kidney failure. Any therapy that slows those trajectories can change both patient outcomes and payer burden, especially when its modeled ICER stays in a range that health systems generally view as acceptable. Here, the economic signal aligned with the known cardiorenal effect of finerenone rather than relying on speculative assumptions.
The remaining question for decision-makers is not whether finerenone can fit into the treatment pathway, but how broadly it should be used across eligible patients with stage 3 or 4 CKD and albuminuria in routine practice. Real-world uptake, background SGLT2 inhibitor use, and local pricing will continue to shape reimbursement decisions, yet the FINE-CKD model provides a clear quantitative frame for those discussions.